Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
BMC Public Health ; 16: 54, 2016 Jan 20.
Article in English | MEDLINE | ID: mdl-26790622

ABSTRACT

BACKGROUND: Obesity can be considered a global public health problem that affects virtually all countries worldwide and results in greater use of healthcare services and higher healthcare costs. We aimed to describe average monthly household medicine expenses according to source of funding, public or private, and to estimate the influence of the presence of obese residents in households on total medicine expenses. METHODS: This study was based on data from the 2008-2009 Brazilian Household Budget Survey, with a representative population sample of 55,970 households as study units. Information on nutritional status and medicines acquired and their cost in the past 30 days were analyzed. A two-part model was employed to assess the influence of obesity on medicine expenses, with monthly household medicine expenses per capita as outcome, presence of obese in the household as explanatory variable, and adjustment for confounding variables. RESULTS: Out-of-pocket expenses on medicines were always higher than the cost of medicines obtained through the public sector, and 32 % of households had at least one obese as resident. Monthly household expenses on medicines per capita in households with obese was US$ 20.40, 16 % higher than in households with no obese. An adjusted model confirmed that the presence of obese in the households increased medicine expenses. CONCLUSION: Obesity is associated with additional medicine expenses, increasing the negative impact on household budgets and public expenditure.


Subject(s)
Fees, Pharmaceutical/statistics & numerical data , Financing, Personal/statistics & numerical data , Medical Assistance/statistics & numerical data , Obesity/epidemiology , Adolescent , Adult , Aged , Brazil , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Residence Characteristics , Socioeconomic Factors , Surveys and Questionnaires , Young Adult
3.
Front Public Health ; 6: 205, 2018.
Article in English | MEDLINE | ID: mdl-30101142

ABSTRACT

Background: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied. OBJECTIVE: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.

4.
Appl Health Econ Health Policy ; 15(2): 163-172, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27798797

ABSTRACT

BACKGROUND: Little is known about the quality and quantity of cost-utility analyses (CUAs) in Brazil. OBJECTIVE: The objective of this study was to provide a systematic review of published CUAs of healthcare technologies in Brazil. METHODS: We performed a systematic review of economic evaluations studies published in MEDLINE, EMBASE, LILACS (Latin American and Caribbean Health Sciences Literature), SciELO (Scientific Electronic Library Online), NHS EED (National Health Service Economic Evaluation Database), HTA (Health Technology Assessment) Database, Web of Science, Scopus, Bireme (Biblioteca Regional de Medicina), BVS ECOS (Health Economics database of the Brazilian Virtual Library of Health), and SISREBRATS (Sistema de Informação da Rede Brasileira de Avaliação de Tecnologias em Saúde [Brazilian Network for the Evaluation of Health Technologies]) from 1980 to 2013. Articles were included if they were CUAs according to the classification devised by Drummond et al. Two independent reviewers screened articles for relevance and carried out data extraction. Disagreements were resolved through discussion or through consultation with a third reviewer. We performed a qualitative narrative synthesis. RESULTS: Of the 535 health economic evaluations (HEEs) relating to Brazil, only 40 were CUAs and therefore included in the analysis. Most studies adhered to methodological guidelines for quality of reporting and 77.5% used quality-adjusted life-years (QALYs) as the health outcome. Of these studies, 51.6% did not report the population used to elicit preferences for outcomes and 45.2% used a specific population such as expert opinion. The preference elicitation method was not reported in 58.1% of these studies. The majority (80.6%) of studies did not report the instrument used to derive health state valuations and no publication reported whether tariffs (or preference weights) were national or international. No study mentioned the methodology used to estimate QALYs. CONCLUSIONS: Many published Brazilian cost-utility studies adhere to key recommended general methods for HEE; however, the use of QALY calculations is far from being the current international standard. Development of health preferences research can contribute to quality improvement of health technology assessment reports in Brazil.


Subject(s)
Cost-Benefit Analysis , Brazil , Cost-Benefit Analysis/methods , Cost-Benefit Analysis/standards , Cost-Benefit Analysis/statistics & numerical data , Humans , Quality-Adjusted Life Years , Technology Assessment, Biomedical/methods , Technology Assessment, Biomedical/standards , Technology Assessment, Biomedical/statistics & numerical data , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL